TopFunds

Abbott Laboratories

NYSE: ABT

Stock price

116.13 USD

(+0%) TODAY

Medical - Devices

Financial Performance

Share

5Y price score: (9)

Help

The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.

A score of 100 indicates that the stock did as well as the S&P 500 Index.

A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.

10Y return: 208.9%

DATE RANGE:

US$ Per
Share

    Time scale:

    By default your notes are visible only to you.

    81.9

    52-week range

    137.4

    116.13

    Your model inputs

    Required return / cost of capital
    %
    FCFF terminal growth rate
    %

    Your fair value & Margin of safety

    To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.

    Forecast:

    Valuation

    Free Cash Flow Yield

    Help
    FCF Yield TTM = Trailing Twelve Months free cash flow per share / current market price per shareLearn more

    4.3 %

    Dividend Yield TTM

    2.1 %

    Market cap $

    $ 200,949

    Price / Earnings TTM

    Help
    P/E TTM = current market price per share / Trailing Twelve Months diluted earnings per shareLearn more

    37.3

    Price / Book TTM

    4

    PEG TTM

    Help
    Price/Earnings-to-Growth ratio = P/E TTM divided by most recent annual diluted earnings per share growth rateLearn more

    (0.8)

    Earnings growth and return

    LTM

    5YR

    10YR

    Total return (price & dividends)

    (10.1) %

    1.3 %

    208.9 %

    Free cash flow per share growth

    87.7 %

    32.1 %

    243.5 %

    Earnings per share growth

    (47.5) %

    48.8 %

    26.5 %

    Founded: 1,888

    Employees: 114,000

    Business Summary:Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

    Fair Value Reference Estimate

    Latest Earnings Call Takeaways

    2026 Q2 (Jul 16, 2026)

    1) Strategy & Leadership - Abbott's CEO Robert Ford emphasized the company's commitment to disciplined execution and innovation across its product portfolio. - The company is focused on a steady cadence of product launches, including the Amulet 360 left atrial appendage device and the Tactiflex Duo PFA catheter, with expectations to launch several new products over the next 12 months. - Abbott is reaffirming its full-year guidance for comparable sales growth of 6.5% to 7.5% and has raised its EPS guidance to $5.45 to $5.60.

    2) Financial & Segment Results - Abbott reported a sales growth of 4.8% in Q2 2026, with adjusted EPS of $1.31, exceeding guidance and consensus estimates. - The adjusted gross margin improved to 58.0%, up 100 basis points YoY, driven by a favorable business mix and operational improvements. - Key segment performances include: | Segment | Sales Growth (YoY) | |-----------------------|---------------------| | Diagnostics | 7.5% (Core Lab) | | Cancer Diagnostics | 13% (Cologuard) | | Nutrition | 6.5% (International)| | EPD | 9% | | Medical Devices | 8.5% |

    3) Problems / Headwinds - The rapid and molecular diagnostics segment saw an 8% decline due to decreased respiratory testing volumes. - The company continues to face challenges in the Chinese market, particularly with the VBP impacting sales, although the decline is expected to lessen. - Competitive pressures in the structural heart market and the need for improved commercial execution were noted.

    4) Operational or Product Plans - Abbott is focused on launching new products, including the Libre Duo glucose monitoring sensor and several devices in the electrophysiology space. - The company plans to begin patient enrollment in several clinical trials in Q4, which will support future product launches. - There is a strong emphasis on expanding the continuous glucose monitoring (CGM) market through reimbursement discussions and product innovation.

    5) Guidance & Outlook / Investor Angle - Abbott is optimistic about the second half of 2026, expecting growth acceleration driven by nutrition, electrophysiology, core lab, and cancer diagnostics. - The company aims for high single-digit growth in the long term, with a focus on maintaining a sustainable growth trajectory. - The outlook for 2027 includes expectations for improved growth rates across segments, particularly in nutrition and diagnostics.

    Bottom line: Abbott's Q2 results reflect strong operational momentum and a commitment to innovation, with an optimistic outlook for the second half of 2026 and beyond, making it a potentially attractive investment for shareholders.

    Annual Reports, Presentations And IR Contacts

    Go to the website
    Annual report links (10K)
    2025202420232022202120202019201820172016

    Abbott Laboratories — Financial Overview, Stock Price, Market Cap

    Abbott Laboratories is a company. Founded in 1888. As of August 26, 2026, the company's market capitalization is $200949420990 with a current stock price of $116.13.